请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
banner
当前位置: 首页 > 产品中心 > Angiogenesis > MedKoo/CH5164840/1/406498

MedKoo/CH5164840/1/406498

  • 产品编号: 406498
  • 美  元  价: 待定
  • 市  场  价: ¥0.00
  • 品       牌:
  • 产       地: 美国(厂家直采)
  • 公       司: MedKoo Biosciences, Inc
  • 产品分类:
  • 公司分类: Angiogenesis
MedKoo/CH5164840/1/406498
  • MedKoo/CH5164840/1/406498
商品介绍

CH5164840

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406498

CAS#:1052645-73-4

Description:CH5164840 is a potent and selective HSP90 inhibitor. CH5164840 showed remarkable antitumor activity against NSCLC cell lines and xenograft models. CH5164840 has potent antitumor activity and is highly effective in combination with erlotinib against NSCLC tumors with EGFR overexpression and mutations.

Price and Availability

SizePriceShipping out timeQuantity
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

CH5164840, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406498Name: CH5164840CAS#: 1052645-73-4Chemical Formula: C19H23N5O2SExact Mass: 385.15725Molecular Weight: 385.48322Elemental Analysis: C, 59.20; H, 6.01; N, 18.17; O, 8.30; S, 8.32

Synonym:CH5164840; CH-5164840; CH 5164840.

IUPAC/Chemical Name:7 -​Thia-​3,​5,​11,​15-​tetraazatricyclo[15.​3.1.12,​6]​docosa-​1(21)​,​2,​4,​6(22)​,​17,​19-​hexaene-​10,​16-​dione, 4-​amino-​18,​20-​dimethyl-.

InChi Key:OMFBVBRFVYLRQT-UHFFFAOYSA-N

InChi Code:InChI=1S/C19H23N5O2S/c1-11-8-12(2)14-9-13(11)15-10-17(24-19(20)23-15)27-7-4-16(25)21-5-3-6-22-18(14)26/h8-10H,3-7H2,1-2H3,(H,21,25)(H,22,26)(H2,20,23,24)

SMILES Code:NC1=NC(C(C=C2C(NCCCN3)=O)=C(C)C=C2C)=CC(SCCC3=O)=N1

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

   Structure comparison between   CH5015765 ,  CH5138303 and CH5164804   

References

1: Kanamaru C, Yamada Y, Hayashi S, Matsushita T,Suda A, Nagayasu M, Kimura K, Chiba S. Retinal toxicity induced bysmall-molecule Hsp90 inhibitors in beagle dogs. J Toxicol Sci.2014;39(1):59-69. PubMed PMID: 24418710.

2: Saitoh R, Nagayasu M, Shibahara N, Ono N, Suda A, Kato M, Ishigai M.Assessing the Impact of HER2 Status on the Antitumor Activity of anHSP90 Inhibitor in Human Tumor Xenograft Mice using Pharmacokinetics-PharmacodynamicModeling. Drug Metab Pharmacokinet. 2013 Oct 15. [Epub ahead of print]PubMed PMID: 24126359.

3: Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, TsukudaT, Mio T, Ishii N, Kondoh O, Aoki Y. Enhanced antitumor activity oferlotinib in combination with the Hsp90 inhibitor CH5164840 againstnon-small-cell lung cancer. Cancer Sci. 2013 Oct;104(10):1346-52. doi:10.1111/cas.12237. Epub 2013 Aug 20. PubMed PMID: 23863134.

4: Suda A, Koyano H, Hayase T, Hada K, Kawasaki K, Komiyama S, HasegawaK, Fukami TA, Sato S, Miura T, Ono N, Yamazaki T, Saitoh R, Shimma N,Shiratori Y, Tsukuda T. Design and synthesis of novel macrocyclic2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett. 2012Jan 15;22(2):1136-41. doi: 10.1016/j.bmcl.2011.11.100. Epub 2011 Dec 1.PubMed PMID: 22192591.

5: Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, SudaA, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, IshiiN, Kondoh O, Aoki Y. Preclinical antitumor activity of the novel heatshock protein 90 inhibitor CH5164840 against human epidermal growthfactor receptor 2 (HER2)-overexpressing cancers. Cancer Sci. 2012Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec13. PubMed PMID: 22050138.

品牌介绍


MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。

MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。




蚂蚁淘(ebiomall)作为一家生命科学领域的垂直电商平台,公司专注生物医学科研用品的全球导购和品牌推广,为海内外厂方与代理经销商搭建跨境贸易系统和交流平台。产品齐全,200+分类,1000+品牌,500万+产品信息。100%正品,专业售后,到货快,在线下单, 简单轻松,节省科学家宝贵的科研时间。为您竭诚服务!

【订购】蚂蚁淘生物科技  联系方式:4000-520-616

更多产品,更多优惠!请联系我们!

苏州蚂蚁淘生物科技有限公司

免费热线:4000-520-616

官网:https://www.ebiomall.cn/



MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采模式 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔
在线客服
客服电话

4000-520-616

0512-67156496